Supplementary materials
收藏资源简介:
Efficacy and prognostic factors of postoperative radiotherapy for high-risk cutaneous squamous cell carcinoma: a systematic review and meta-analysis eFigure1. Adjusted analysis of overall survival and disease-free survival: Overall survival analysis exclude study by Kyrgidis 2010 using the random effects model eFigure2. Forest plots for prognostic factors relevant to disease-free survival: Concerning the deleterious impact of PNI demonstrated by our analysis, the AJCC staging system for cSCC also regards PNI as a high risk factor. Besides, our analysis of PNI also was determined robustly since the presence of PNI increases T stage of cSCC in the NCCN guidelines. Surprisingly, immunosuppression in this study showed a high heterogeneity indicating the uncertainty of its influence, whereas the recent AJCC Cancer Staging Manual recommanded this risk factor as additional aspect for clinical care in patients with cSCC of the head and neck region. We included IS as a general category without specific stratification and most selected articles also had not defined the IS. Although Estall et al1 presented IS associated with an increased risk of metastases on the basis of well-defined patients with coexisting hematological malignancy, immunosuppressant use, and end stage renal failure requiring dialysis, it is difficult for a meta-analysis to anlyze all cohorts with vague definition of IS. In this situation, the data suggested that clarification of the types of IS is essential for the comprehension of the factors influencing DFS. A high heterogeneity was observed among included studies concerning the treatment of adjuvant radiotherapy. Some reporters implied that adjuvant radiotherapy showed significant benefit in DFS, while Harris et al and Trosman et al found little association between adjuvant radiotherapy and DFS. It is consistent with the 2018 NCCN guidelines, in which the diversity of study populations was addressed to complicate the comparison of treatment outcomes. Nonetheless, the more accurate N-stage information is crucial for further analysis to identify whether patients with regional metastases would benefit from adjuvant radiotherapy with increased DFS. eFigure3. Funnel plot of recurrence analyses eTable1. Prognostic hazard ratio summarize eTable2. New-castle Ottawa Scale scoring of included studies
高危皮肤鳞状细胞癌(cutaneous squamous cell carcinoma)术后放疗的疗效与预后因素:一项系统综述与荟萃分析 eFigure1. 总生存期与无病生存期的校正分析:采用随机效应模型(random effects model)排除Kyrgidis 2010年的研究开展总生存期分析 eFigure2. 与无病生存期相关的预后因素森林图:鉴于本研究分析揭示的神经周围侵犯(perineural invasion, PNI)不良影响,美国癌症联合委员会(American Joint Committee on Cancer, AJCC)皮肤鳞状细胞癌分期系统亦将PNI列为高危因素。此外,根据NCCN指南,PNI的存在会提升皮肤鳞状细胞癌的T分期,因此本研究关于PNI的分析结果具备较强稳健性。值得注意的是,本研究中免疫抑制(immunosuppression)相关数据呈现较高异质性,提示其对预后的影响尚不明确,但最新版《AJCC癌症分期手册》已将该风险因素列为头颈部皮肤鳞状细胞癌患者临床诊疗的额外参考维度。本次研究将免疫抑制作为未做具体分层的通用类别纳入分析,且多数纳入文献亦未对免疫抑制作出明确定义。尽管Estall等人[1]基于合并血液系统恶性肿瘤、免疫抑制剂使用以及需透析的终末期肾衰竭的明确患者队列,证实免疫抑制与转移风险升高存在关联,但荟萃分析难以纳入所有免疫抑制定义模糊的研究队列。在此背景下,研究数据表明,明确免疫抑制的类型对于理解影响无病生存期的相关因素至关重要。 纳入研究中关于辅助放疗的治疗方案同样存在较高异质性。部分研究指出辅助放疗可显著改善无病生存期,而Harris与Trosman等人的研究则未发现辅助放疗与无病生存期之间存在明显关联。这一结果与2018年美国国家综合癌症网络(National Comprehensive Cancer Network, NCCN)指南相符,该指南指出研究人群的异质性会使治疗结局的比较更为复杂。尽管如此,更为精准的N分期信息对于进一步分析存在区域转移的患者是否能通过辅助放疗提升无病生存期而言至关重要。 eFigure3. 复发分析漏斗图 eTable1. 预后风险比(hazard ratio)汇总 eTable2. 纳入研究的纽卡斯尔-渥太华量表(Newcastle Ottawa Scale)评分



